Literature DB >> 25549725

A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.

Rabya H Sayed1, Dominic Rogers2, Fakhar Khan2, Ashutosh D Wechalekar1, Helen J Lachmann1, Marianna Fontana1, Shameem Mahmood1, Sajitha Sachchithanantham1, Ketna Patel1, Philip N Hawkins1, Carol J Whelan3, Julian D Gillmore4.   

Abstract

AIMS: AL amyloidosis may respond to chemotherapy but two-thirds of patients with severe cardiac involvement die within a year of diagnosis, purportedly from tachyarrhythmias or electromechanical dissociation. We sought to characterize the nature of cardiac arrhythmias in severe cardiac AL amyloidosis using implanted cardiac rhythm recorders. METHODS AND
RESULTS: Implantable loop recorders (ILRs) were inserted within 24 h of baseline evaluation at the UK National Amyloidosis Centre, into 20 consecutive patients with newly diagnosed severe cardiac AL amyloidosis and symptoms of syncope or pre-syncope. Weekly ILR recordings and additional recordings at the time of symptoms were obtained. Median (range) follow-up from baseline was 308 (10-399) days. Thirteen patients died, and median survival in the whole cohort was 61 days from device insertion. In each of eight evaluable cases, death was heralded by bradycardia, usually associated with complete atrioventricular block (CAVB), followed shortly thereafter by pulseless electrical activity. Four patients received pacemakers, a median (range) of 7 (3-38) h after development of symptomatic CAVB, but these did not prevent rapid cardiac decompensation and death in three cases. Despite 272 loop recordings, there was only one episode of non-sustained ventricular tachycardia, which was preceded by severe bradycardia. Patients who died had significantly worse global left ventricular strain on echocardiography (P = 0.029) and reduced 6 min walk distance (P = 0.048) at baseline compared with survivors.
CONCLUSIONS: The discovery that bradyarrhythmias heralded terminal cardiac decompensation in most patients with severe cardiac AL amyloidosis supports a study of prophylactic pacemaker insertion in this patient population. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Amyloidosis; Bradycardia; Cardiomyopathy; Implantable loop recorder

Mesh:

Substances:

Year:  2014        PMID: 25549725     DOI: 10.1093/eurheartj/ehu506

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  30 in total

Review 1.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

Review 2.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 3.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

4.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Authors:  Edward A El-Am; Angela Dispenzieri; Rowlens M Melduni; Naser M Ammash; Roger D White; David O Hodge; Peter A Noseworthy; Grace Lin; Sorin V Pislaru; Alexander C Egbe; Martha Grogan; Vuyisile T Nkomo
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

Review 5.  Transthyretin Cardiac Amyloidosis.

Authors:  Anit K Mankad; Keyur B Shah
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 6.  [Indications for implantable loop recorders in patients with channelopathies and ventricular tachycardias].

Authors:  Julia Köbe; Kristina Wasmer; Florian Reinke; Lars Eckardt
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-12

7.  Position Statement on Diagnosis and Treatment of Cardiac Amyloidosis - 2021.

Authors:  Marcus V Simões; Fabio Fernandes; Fabiana G Marcondes-Braga; Philip Scheinberg; Edileide de Barros Correia; Luis Eduardo P Rohde; Fernando Bacal; Silvia Marinho Martins Alves; Sandrigo Mangini; Andréia Biolo; Luis Beck-da-Silva; Roberta Shcolnik Szor; Wilson Marques Junior; Acary Souza Bulle Oliveira; Márcia Waddington Cruz; Bruno Vaz Kerges Bueno; Ludhmila Abrahão Hajjar; Aurora Felice Castro Issa; Felix José Alvarez Ramires; Otavio Rizzi Coelho Filho; André Schmidt; Ibraim Masciarelli Francisco Pinto; Carlos Eduardo Rochitte; Marcelo Luiz Campos Vieira; Cláudio Tinoco Mesquita; Celso Dario Ramos; José Soares-Junior; Minna Moreira Dias Romano; Wilson Mathias Junior; Marcelo Iório Garcia Junior; Marcelo Westerlund Montera; Marcelo Dantas Tavares de Melo; Sandra Marques E Silva; Pedro Manoel Marques Garibaldi; Aristóteles Comte de Alencar Neto; Renato Delascio Lopes; Diane Xavier de Ávila; Denizar Viana; José Francisco Kerr Saraiva; Manoel Fernandes Canesin; Glaucia Maria Moraes de Oliveira; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

Review 8.  Association of Arrhythmias in Cardiac Amyloidosis and Cardiac Sarcoidosis.

Authors:  Ibtisam Ashraf; Mercedes Maria Peck; Ruchira Maram; Alaa Mohamed; Diego Ochoa Crespo; Gurleen Kaur; Bilal Haider Malik
Journal:  Cureus       Date:  2020-08-18

9.  Holter Monitoring and Loop Recorders: From Research to Clinical Practice.

Authors:  Alessio Galli; Francesco Ambrosini; Federico Lombardi
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 10.  CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy.

Authors:  Laura Keil; Céleste Chevalier; Paulus Kirchhof; Stefan Blankenberg; Gunnar Lund; Kai Müllerleile; Christina Magnussen
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.